Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid-19


The views and opinions expressed in this blog / article are those of the authors and do not necessarily reflect the official policy or position of any other agency, organization, employer or company. Merck KGaA, Darmstadt, Germany and its Affiliates shall not be liable for any errors, omissions or delays in the information, or damage arising from its display or use. All information is provided on an as-is basis.


We follow up our Part 1 discussion of the impact of Covid-19 on bioprocessing, based on our recent White Paper that is also included in our research, (see We interviewed major biopharmaceutical industry senior bioprocessing decision-makers, and bioprocessing suppliers in the US and Europe. The impact on emerging biopharma companies as well as smaller suppliers may actually be a small silver-lining for some, during this global, horrific event.  The demand on the industry segment for capacity, support and services has trickled down from the largest suppliers to the mid-tier, and even smaller providers of equipment, services, diagnostics, reagents, devices and capacity. For those on the front lines of bioprocessing, our interviews report some of the key fears, and options for their resolution that may result in a future “new normal” for bioprocessing. Worsening shortage of single-use technologies and is a key fear that will require resolution. Already there are long wait times for many single-use supplies, and these will likely lengthen (for non-pandemic response-related projects).

Fig 2: Key Fears and Resolutions in Bioprocessing Post Covid-19

What came to the front include:

  • “Shortage of SUS & other supplies” inability to obtain needed SUS (75% of users)
  • “Prioritization will hurt.” [non-Covid-19 projects] prioritized activities pushing pandemic/ biodefense to front of the line.
  • Real Shortages: Prioritization combined with worsening shortages (order lead/wait times) resulting problems w/equipment and CMO services
  • Developers’ fears: shortages and prioritization – end-users need reassurance from their suppliers.

In the future, respondents, both biopharma company and suppliers, expect to see a different ‘new normal’.  Changes include collaborations among stake-holders are likely to increase. Today, as the world works through this crisis, collaborations are seen as indispensable.  This includes cross-company, cross-industry, with governments, and multi-nationally.  There is a clear sense that we are all in this together, and that the current situation may be well be defining our relationships in the future.  If any positive outcome results from this pandemic, it may be the recognition that working together is essential today, and this will likely carry out into the future.  Many also foresee practical benefits, including improved public perceptions of the (bio)pharmaceutical industry.

Pandemic-related Trends

Some pandemic-related changes or trends with long term, strategic implications include:

Pandemic Related Trends: Big Picture

  • Bioprocessing accelerating globally: By mid-May, more than 215 novel and repurposed Covid-19 therapies in the pipeline…investment, political interest
  • Outsourcing: Use of CMOs accelerating both for pandemic-related projects, and lower priority projects. 70% believe outsourcing will accelerate long-term.
  • Regionalization: More bioprocessing, more multi-site facilities internationally, more facilities to serve regional markets, including China; pandemic accelerating the trend toward supply chain and bioprocessing facilities’ diffusion worldwide.
  • Supply chain security/strengthening: Emphasis on secure supplies, backup sources. Transparency in supply chains; coordination among suppliers and customer.  Political and economic demand for supply chain security:  APIs, raw ingredients, materials, plastics

      …all being evaluated for in-shoring.


Even before the current Covid-19 pandemic all of these trends were evident.  Based on our current research, we found changes being undertaken resulting from the pandemic that are impacting near-term industry dynamics.  But the future-casting offered by industry executives presented some significant, long-term transformational changes that are likely to occur, as well.

  • “More Collaborations” 70% of Suppliers expect to work more collaboratively with:
    • Their customers
    • Vendors
    • Raw materials suppliers (including supply chain security and transparency)
  • “More R&D”
    • More investment


Ronald A. Rader is the Senior Director, Technical Research, BioPlan Associates. He has 35+ years’ experience as a biotechnology and pharmaceutical, particularly biopharmaceutical, information specialist, analyst and publisher, and has been responsible for the Antiviral Agents Bulletin periodical; Federal Bio-Technology Transfer Directory; BIOPHARMA: Biopharmaceutical Products in the U.S. and European Market; and the Biosimilars/Biobetters Pipeline Directory

Ronald Rader, Kamna Jhamb and Eric Langer

Dr. Kamna Jhamb is a life sciences and healthcare market researcher. With a PhD in Biotechnology/Microbiology, she has extensive experience working in several key industry segments, and has experience at the Lawrence Berkeley National Lab (LBNL), Berkeley, CA and elsewhere. Her expertise lies in primary and secondary research, and market analysis of healthcare and biopharma segments. She contributes to international publications and journals, and researches for in-depth reports, analyses and strategic White Papers.

President and Managing Partner at BioPlan Associates, Inc. | Website

Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing,” and many other industry reports.

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

Covid-19 Impact on Bioprocessing: PART 1 Accelerating Trends

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

The views and opinions expressed in this blog / article are those of the authors and do not…

How the Vaccine Industry and Biotechs Can Accelerate Pandemic Responses

The impact of the Covid-19 pandemic has highlighted the need for a fast and effective vaccine development process….

Scroll to Top